Results 221 to 230 of about 3,841,835 (347)

Understanding of Zaire ebolavirus–human protein interaction for drug repurposing

, 2020
Mathavan Muthaiyan, Shilpa Sri Pushan, Leimarembi Devi Naorem, Amouda Venkatesan   +3 more
openalex   +2 more sources

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

Clinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen, Menno van Diemen, Liza Botros, Ingrid Tomljanovic, Hind Achbo, Dimitra Eleftheriou, Paul Willem Schenk, Naomi Bertine Klarenbeek, Derek William Gilroy, Manon Aleida Adriana Jansen, Matthijs Moerland   +10 more
wiley   +1 more source

Data-driven strategies for drug repurposing: insights, recommendations, and case studies. [PDF]

Brief Bioinform
Savander S, Curabaz NN, Abbasi AM, Khan A, Saeed K, Tanoli Z.   +5 more
europepmc   +1 more source

Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing

Xiaolan Hu, Jian‐Lin Wu, Quan He, Zhi‐Qi Xiong, Na Li   +4 more
openalex   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric drug development has achieved remarkable success in the last 20 years with over 1,000 products studied in pediatric patients. This success has been driven in part by an increased understanding of pediatric disease processes. The aspect that has been largely overlooked is the potential adverse effect of new drugs on pediatric developmental ...
Gilbert J. Burckart, Susan M. Abdel‐Rahman, Gelareh Abulwerdi, Sherbet Samuels, Rebecca Racz, Mohamed A. Mohamoud, Nicholas P. Tatonetti   +6 more
wiley   +1 more source

Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy. [PDF]

Pharmaceuticals (Basel)
Cheng OJ, Tran TTT, Chen YA, Tan AC.
europepmc   +1 more source

Bioinformatic identification and evaluation of potential therapeutic targets in primary congenital glaucoma for drug repurposing

Gomboc, Ines
openalex   +1 more source

Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis

Clinical Pharmacology &Therapeutics, EarlyView.
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Tara Lazetic, Deanne Nixie R. Miao, Britt I. Drögemöller, Alain Dabdoub, Julia M. Abitbol   +4 more
wiley   +1 more source

Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies. [PDF]

Fundam Clin Pharmacol
E Silva DM, de Souza Lacerda L, de Souza Andrioli A, Braz WR, Campos LM, de Paiva MRB, Pittella F, Fabri RL, Tavares GD.   +8 more
europepmc   +1 more source